对于铂类难治性转移性或复发性头颈部鳞状细胞癌患者使用多西他赛进行每周治疗。

Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck.

作者信息

Cho Byoung Chul, Keum Ki Chang, Shin Sang Joon, Choi Hye Jin, Lee Young Joo, Kim Se Hun, Choi Eun Chang, Kim Joo Hang

机构信息

Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seodaemun-gu Shinchon-dong 134, Seoul, Korea.

出版信息

Cancer Chemother Pharmacol. 2009 Dec;65(1):27-32. doi: 10.1007/s00280-009-0999-4. Epub 2009 Apr 21.

DOI:10.1007/s00280-009-0999-4

PMID:19381630

Abstract

BACKGROUND

The objective of the study was to investigate the efficacy and tolerability of weekly docetaxel in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

METHODS

Patients fulfilling the following criteria were enrolled: histologically confirmed SCCHN; documented progressive disease (PD) after platinum-based treatment; Eastern Cooperative Oncology Group (ECOG) 0-2; measurable disease; not candidates for local therapy. Docetaxel (35 mg/m(2)) was administered for 3 weeks, every 4 weeks for a maximum of 6 cycles.

RESULTS

A total of 23 patients were treated. All patients were assessable for toxicity and response. The overall response rate was 13.0% (3/23) and disease control rate was 34.7% (8/23). Median progression-free and overall survival (OS) was 9 (95% CI, 7.6-10.4 weeks) and 29 weeks (95% CI, 10.8-47.1 weeks), respectively. Most common hematological toxicities were grade 1-2 anemia (6/23, 26.1%) and nonhematological toxicities were mild and manageable. There was no treatment-related death.

CONCLUSION

Weekly docetaxel regimen had good clinical activity with an acceptable toxicity in patients with platinum-refractory SCCHN.

摘要

背景

本研究的目的是调查每周使用多西他赛治疗铂类难治性复发性或转移性头颈部鳞状细胞癌（SCCHN）患者的疗效和耐受性。

方法

符合以下标准的患者入组：组织学确诊为SCCHN；铂类治疗后记录有疾病进展（PD）；东部肿瘤协作组（ECOG）体能状态评分为0 - 2；疾病可测量；不适合局部治疗。多西他赛（35 mg/m²）给药3周，每4周重复，最多6个周期。

结果

共治疗23例患者。所有患者均可评估毒性和反应。总缓解率为13.0%（3/23），疾病控制率为34.7%（8/23）。无进展生存期和总生存期（OS）的中位数分别为9周（95%CI，7.6 - 10.4周）和29周（95%CI，10.8 - 47.1周）。最常见的血液学毒性为1 - 2级贫血（6/23，26.1%），非血液学毒性轻微且可控。无治疗相关死亡。